Seno Medical Instruments (San Antonio), a company developing opto-acoustic technology as a new tool for diagnosing breast cancer, has completed active enrollment of subjects in its U.S.-based PIONEER pivotal study of Imagio. The study was designed to determine if this technology will provide information to the physician to determine if a woman may avoid negative biopsies. Data from the study will serve as the basis for the company's premarket approval application (PMA) to the FDA, Seno noted. Read More
